Home › Depression › NCT04761328

Fear of Recurrence and Stopping Immunotherapy

Distress Associated With Stopping Immunotherapy of Cancer Patients

Who can join

Ages 21 and older · All sexes

Inclusion Criteria:

* Age 21 years and older
* Fluent in English
* Diagnosis of cancer and history of treatment with immunotherapy

Exclusion Criteria:

* Active suicidal ideation, delusions or hallucinations

About the study

The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.

What is being tested

• cognitive behavioral therapy (behavioral)

Sponsor: University of Pittsburgh · Participants: 100 · Started: Aug 2, 2021

Contact the study team

• Jennifer L Steel, Ph.D. · Phone: 412-692-2041
• Jason Luke, MD · Phone: 412-623-4511

Official record on ClinicalTrials.gov — NCT04761328

Locations in the U.S.

Conditions

• Depression
• Anxiety

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.